# Characterization, Preconditioning, Safety, and Other Issues of MSC-Derived EVs and Secretome

**Authors:** Elena V. Alpeeva, Anfisa S. Ryabchenko, Ekaterina A. Vorotelyak

PMC · DOI: 10.3390/ijms27041688 · International Journal of Molecular Sciences · 2026-02-09

## TL;DR

This review discusses the potential of extracellular vesicles from mesenchymal stromal cells for therapy, focusing on their characterization, safety, and production challenges.

## Contribution

The paper provides a comprehensive review of recent advancements and safety concerns in MSC-derived EVs and their secretome.

## Key findings

- MSC-derived EVs show therapeutic potential due to their ability to cross barriers and deliver cargo.
- Clinical use is limited by batch variability and safety risks like tumorigenesis.
- Immortalized MSCs may offer consistent EV production but raise safety concerns.

## Abstract

Recently, a growing number of scientific research and clinical studies have demonstrated the potential of extracellular vesicles (EVs) secreted by cells of different types for treating various diseases. It was shown that most frequently, substances and molecules excreted by the cells exert therapeutic or other effects, and not the cells themselves. Their cargo is wrapped in membrane envelopes, allowing it to survive for a longer time and find targets in organs and tissues as well as overcome various barriers, including the blood–brain barrier. EVs from mesenchymal stromal (stem) cells (MSCs) have attracted particular interest, as MSCs possess immunomodulatory and tissue-repairing properties per se. However, their clinical use is severely limited due to the frequent lack of efficiency in clinical trials, as well as existing risks of tumorigenesis and pulmonary embolism. EVs isolated from MSCs may help circumvent these problems, but their composition and properties, like those of their progenitors, vary significantly between batches, owing to donor characteristics and cell culture conditions. EVs from immortalized MSCs offer greater potential for repeatability and uniformity but raise the question of whether cell immortalization products enter EVs and are transferred to target cells and/or affect them. This review examines the most recent data on preconditioning techniques for MSC-derived EVs, EV characterization, large-scale manufacturing, storage, and the use of EVs from immortalized MSCs, including their characteristics and therapeutic properties, with a special emphasis on safety issues.

## Full-text entities

- **Genes:** CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, MIR214 (microRNA 214) [NCBI Gene 406996] {aka MIRN214, miRNA214, mir-214}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, METTL14 (methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit) [NCBI Gene 57721] {aka hMETTL14}, SDCBP (syndecan binding protein) [NCBI Gene 6386] {aka MDA-9, MDA9, SDCBP1, ST1, SYCL, TACIP18}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MIR23A (microRNA 23a) [NCBI Gene 407010] {aka MIRN23A, hsa-mir-23a, miRNA23A, mir-23a}, MIR222 (microRNA 222) [NCBI Gene 407007] {aka MIRN222, miRNA222, mir-222}, CD14 (CD14 molecule) [NCBI Gene 929], CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, Kit (Kit proto-oncogene receptor tyrosine kinase) [NCBI Gene 16590] {aka Bs, CD117, Fdc, Gsfsco1, Gsfsco5, Gsfsow3}, PRAP1 (proline rich acidic protein 1) [NCBI Gene 118471] {aka PRO1195, UPA}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, ALCAM (activated leukocyte cell adhesion molecule) [NCBI Gene 214] {aka CD166, MEMD}, PDCD6IP (programmed cell death 6 interacting protein) [NCBI Gene 10015] {aka AIP1, ALIX, DRIP4, HP95, MCPH29}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, Nos3 (nitric oxide synthase 3) [NCBI Gene 24600] {aka eNos}, MIR378A (microRNA 378a) [NCBI Gene 494327] {aka MIR378, MIRN378, hsa-mir-378, hsa-mir-378a, miRNA378}, MCAM (melanoma cell adhesion molecule) [NCBI Gene 4162] {aka CD146, HEMCAM, METCAM, MUC18, MelCAM}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, MIR215 (microRNA 215) [NCBI Gene 406997] {aka MIRN215, miRNA215, mir-215}, CD47 (CD47 molecule) [NCBI Gene 961] {aka IAP, MER6, OA3}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, CD46 (CD46 molecule) [NCBI Gene 4179] {aka AHUS2, MCP, MIC10, TLX, TRA2.10}, MIR126 (microRNA 126) [NCBI Gene 406913] {aka MIRN126, miRNA126, mir-126}, MIR17 (microRNA 17) [NCBI Gene 406952] {aka MIR17-5p, MIR91, MIRN17, MIRN91, hsa-mir-17, miR-17}, Pum2 (pumilio RNA-binding family member 2) [NCBI Gene 298874], Nfe2l2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 83619], IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, MIR221 (microRNA 221) [NCBI Gene 407006] {aka MIRN221, miRNA221, mir-221}, Myc (Myc proto-oncogene, bHLH transcription factor) [NCBI Gene 17869] {aka Myc2, Niard, Nird, bHLHe39}, NT5E (5'-nucleotidase ecto) [NCBI Gene 4907] {aka CALJA, CD73, E5NT, NT, NT5, NTE}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, Hmox1 (heme oxygenase 1) [NCBI Gene 24451] {aka HEOXG, Heox, Hmox, Ho-1, Ho1, hsp32}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, ROCK1 (Rho associated coiled-coil containing protein kinase 1) [NCBI Gene 6093] {aka P160ROCK, ROCK-I}, Mir21a (microRNA 21a) [NCBI Gene 387140] {aka Mir21, Mirn21, mmu-mir-21, mmu-mir-21a}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, IFIH1 (interferon induced with helicase C domain 1) [NCBI Gene 64135] {aka AGS7, Hlcd, IDDM19, IMD95, MDA-5, MDA5}, RIGI (RNA sensor RIG-I) [NCBI Gene 23586] {aka DDX58, RIG-I, RIG1, RLR-1, SGMRT2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, CD9 (CD9 molecule) [NCBI Gene 928] {aka BTCC-1, DRAP-27, MIC3, MRP-1, TSPAN-29, TSPAN29}, TSG101 (tumor susceptibility 101) [NCBI Gene 7251] {aka TSG10, VPS23}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}, ANGPTL7 (angiopoietin like 7) [NCBI Gene 10218] {aka AngX, CDT6, dJ647M16.1}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}
- **Diseases:** I/R) injury (MESH:D015427), metastasis (MESH:D009362), RA (MESH:D001172), leukemic (MESH:D007938), tumorigenic (MESH:D002471), hyperglycemic (MESH:D006944), retinal ischemia (MESH:D012173), CMSCs (MESH:C564876), ischemic heart disease (MESH:D017202), bladder pain syndrome (MESH:D018856), embolic events (MESH:D004617), glaucoma (MESH:D005901), cognitive dysfunction (MESH:D003072), fibrosis (MESH:D005355), Inflammatory (MESH:D007249), injury to (MESH:D014947), hyperoxia (MESH:D018496), cancer (MESH:D009369), diabetic (MESH:D003920), ischemic myocardium (MESH:D017682), head and neck cancer (MESH:D006258), Hypoxic (MESH:D002534), venous stasis ulcer (MESH:D014647), tumorigenesis (MESH:D063646), pulmonary embolism (MESH:D011655), psoriasis (MESH:D011565), psoriatic (MESH:D015535), AML (MESH:D015470), ischemia (MESH:D007511), Hypoxia (MESH:D000860), cartilage damage (MESH:D002357)
- **Chemicals:** sphingomyelin (MESH:D013109), NO (MESH:D009614), H2S (MESH:D006862), S (MESH:D013455), Melatonin (MESH:D008550), Fe3O4 (-), H2O2 (MESH:D006861), Atorvastatin (MESH:D000069059), dexamethasone (MESH:D003907), phosphatidylcholine (MESH:D010713), ATP (MESH:D000255), lipid (MESH:D008055), LPS (MESH:D008070), tryptophan (MESH:D014364), glucose (MESH:D005947), Doxycycline (MESH:D004318), sulfide (MESH:D013440), O2 (MESH:D010100), poly(I:C) (MESH:D011070), agar (MESH:D000362), cholesterol (MESH:D002784)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], SV40 [taxon 10633]
- **Cell lines:** Jurkat — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_0065), E1-MYC — Mus musculus (Mouse), Hybridoma (CVCL_G671), HFF-1 — Homo sapiens (Human), Finite cell line (CVCL_3285), HFB — Homo sapiens (Human), Plasma cell myeloma, Cancer cell line (CVCL_6257), HSkMEC.2 — Homo sapiens (Human), Transformed cell line (CVCL_A1BD), fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), hTERT — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_EE25), HATMSC1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), HEPC-CB.1 — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_A1AV), HF — Homo sapiens (Human), Diffuse large B-cell lymphoma germinal center B-cell type, Cancer cell line (CVCL_UI84), FaDu — Homo sapiens (Human), Hypopharyngeal squamous cell carcinoma, Cancer cell line (CVCL_1218), SV-HUC-1 — Homo sapiens (Human), Transformed cell line (CVCL_3798)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940780/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12940780/full.md

## References

138 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940780/full.md

---
Source: https://tomesphere.com/paper/PMC12940780